Edgen Stock·Dec 13 2025, 15:03Back
BioMarin Targets 40% Margin With $500M Restructuring
Edgen Stock·Dec 13 2025, 15:03
[1] NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways - The Manila Times (https://www.manilatimes.net/2025/12/13/tmt-ne ...)[2] SanegeneBio raises $110m for RNAi, plus other financings - pharmaphorum (https://pharmaphorum.com/news/sanegenebio-rai ...)[3] The UK-US drug pricing deal: A welcome step, but not the finish line for UK competitiveness - pharmaphorum (https://pharmaphorum.com/market-access/uk-us- ...)
